The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.
J. M. Cuzick
Research Funding - Myriad Genetics
G. Fisher
Research Funding - Myriad Genetics
D. Berney
No relevant relationships to disclose
D. Mesher
Research Funding - Myriad Genetics
H. Møller
No relevant relationships to disclose
J. E. Reid
Employment or Leadership Position - Myriad Genetics
A. Gutin
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
J. S. Lanchbury
Employment or Leadership Position - Myriad Genetics
S. Stone
Employment or Leadership Position - Myriad Genetics